Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has announced a strategic refocusing of its research and development portfolio following the expiration and termination of its option and license arrangements with PinCell S.r.l. relating to the candidate PC111. The decision, effective Aug. 31, was not prompted by any new negative scientific findings regarding PC111, according to the company. Instead, it allows Scinai to concentrate its R&D resources on its proprietary NanoAb platform while preserving capital and management capacity for its contract development and manufacturing organization (CDMO) business.
The refocusing comes as Scinai advances two IL-17 programs within its NanoAb platform, including an intradermal psoriasis program for which approximately €12 million in grant financing is under evaluation in Poland. This strategic shift is expected to streamline operations and enhance the company's ability to develop innovative immunology therapies. Scinai's NanoAb platform is a key asset, and the company aims to leverage its potential to address significant unmet medical needs.
In addition to its R&D efforts, Scinai is strengthening its CDMO business, which provides development and manufacturing services to biotechnology and pharmaceutical companies. As of Aug. 16, the company reported approximately $3.1 million in committed CDMO customer orders. Furthermore, Scinai continues to pursue approximately $5 million in CDMO revenue for 2026, subject to project execution, timing, revenue recognition, and additional business opportunities. This dual focus on innovative therapeutics and revenue-generating services positions Scinai for sustainable growth.
The decision to terminate the PinCell agreement was a strategic move to optimize resource allocation. By focusing on the NanoAb platform and CDMO operations, Scinai aims to enhance shareholder value and accelerate its path to commercialization. The company's pipeline includes therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l., and it owns Scinai Biopharma Services Ltd., a CDMO with facilities in Jerusalem and Yavne, Israel.
Investors and industry observers will be watching how Scinai's refocused strategy unfolds. The company's commitment to its NanoAb platform and CDMO growth underscores its adaptability in a competitive biopharmaceutical landscape. For more details on this announcement, visit the full press release at https://ibn.fm/nnx0Z. For the latest news and updates relating to Scinai, see the company's newsroom at https://ibn.fm/SCNI.
